A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT00277498
• Date of registration: 13/01/2006
• Primary sponsor: Pfizer
• Public title: A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma
• Scientific title: A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Xalacom Given In The Evening, Xalatan Given In The Evening, And Timolol Given In The Morning In Patients With Open Angle Glaucoma Or Ocular Hypertension In The United States.
• Date of first enrolment: December 2005
• Target sample size: 528
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT00277498
• Study type: Interventional
• Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Countries of recruitment

United States

Contacts

• Name: Pfizer CT.gov Call Center
• Affiliation: Pfizer

Key inclusion & exclusion criteria

Inclusion Criteria:

- Uni- or bilateral diagnosis of primary open angle glaucoma or ocular hypertension on
beta-blocker monotherapy or dual therapy in which at least one medication is a
beta-blocker for at least 4 weeks prior to screening

Exclusion Criteria:

- Closed/ barely open anterior chamber angle or history of acute angle closure
glaucoma.

- History of ALT (Argon Laser Trabeculoplasty) or SLT(selective Laser) within 3 months
prior to screening



Age minimum: 18 Years
Age maximum: N/A
Gender: Both

Health Condition(s) or Problem(s) studied

Ocular Hypertension

Open Angle Glaucoma

Intervention(s)

Drug: Timolol

Drug: Xalacom

Drug: Xalatan

Primary Outcome(s)

The mean IOP measurements obtained in the study eye at each time point.

Secondary ID(s)

A6641044

Source(s) of Monetary Support

Please refer to primary and secondary sponsors